TABLE 2.
PD-L1 IC+ and TC+ Prevalence by Anatomic Location
| Breast | Lymph Node | Liver | Lung | Skin | Soft Tissue | Brain | Bone | |
|---|---|---|---|---|---|---|---|---|
| Samples, N | 303 | 60 | 26 | 15 | 14 | 7 | 4 | 4 |
| PD-L1 IC | ||||||||
| Median (IQTL 25%, 75% range) | 1.00 (0.50, 4.00) | 3.00 (0.50, 5.00) | 0.50 (0.0, 1.00) | 2.00 (0.50, 4.00) | 1.00 (1.00, 5.00) | 0.50 (0.00, 1.00) | 1.75 (0.13, 4.50) | 0.25 (0.0, 0.88) |
| IC≥1% (%) | 57.1 | 65.0 | 26.9 | 53.3 | 57.1 | 42.9 | 50.0 | 25.0 |
| PD-L1 TC | ||||||||
| Median (IQTL 25%, 75% range) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.50) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.00) | 0.0 (0.0, 0.0) |
| TC≥1% (%) | 13.5 | 18.3 | 15.4 | 20.0 | 21.4 | 0.0 | 0.0 | 0.0 |
PD-L1 in IC: IC0 (IC <1%), IC1 (IC≥1% and <5%), IC2 (IC≥5% and <10%) and IC3 (IC≥10%). PD-L1 in TC: TC0 (TC <1%), TC1 (TC≥1% and <5%), TC2 (TC≥5% and <50%) and TC3 (TC≥50%).
IC indicates immune cells; IQTL, interquartile; PD-L1, programmed death ligand 1; TC, tumor cells.